Pharmaceutical - Asia-Pacific, Neurological

Filter

Current filters:

Asia-PacificNeurological

Popular Filters

1 to 25 of 52 results

Japan’s market for schizophrenia treatment to double by 2022

Japan’s market for schizophrenia treatment to double by 2022

12-03-2014

Japan’s schizophrenia treatment market value will undergo significant growth over the coming decade,…

Asia-PacificJapanMarkets & MarketingNeurologicalPharmaceutical

Asia-Pacific epilepsy therapeutics market continues to grow as new drugs emerge

28-02-2014

The epilepsy therapeutics market value in the Asia-Pacific region - Australia, China, India and Japan…

Asia-PacificEisaiFycompaGlaxoSmithKlineKeppraMarkets & MarketingNeurologicalPharmaceuticalTrobaltUCBVimpatZonegran

Hisamitsu announces positive Phase II results for Parkinson’s disease drug

10-02-2014

Japanese drugmaker Hisamitsu Pharmaceutical’s has announced the results of a Phase II clinical study…

Asia-PacificHisamitsu PharmaLevodopaNeurologicalPharmaceuticalResearch

Ferrer links with Ildong and Ergomed for lorediplon development

03-02-2014

Privately-held Spanish drugmaker Ferrer has executed two agreements, one with South Korea’s Ildong…

Asia-PacificErgomed Clinical ResearchFerrer InternacionalIldong PharmaLicensinglorediplonNeurologicalPharmaceuticalResearch

UCB and Biogen sign Asian license agreement for MS drugs

UCB and Biogen sign Asian license agreement for MS drugs

30-01-2014

Belgian drugmaker UCB and US biotech firm Biogen Idec have signed exclusive agreements granting UCB the…

AlprolixAsia-PacificBiogen IdecBiotechnologyEloctateLicensingNeurologicalPharmaceuticalTecfideraUCB

Approval of proposals for atomoxetine, sugammadex and to fund baclofen injection in New Zealand

Approval of proposals for atomoxetine, sugammadex and to fund baclofen injection in New Zealand

13-01-2014

New Zealand’s Pharmaceutical Management Agency PHARMAC has announced the approval of proposals to amend…

Asia-PacificBridionEli LillyFinancialGlaxoSmithKlineHealthcareLioresal IntrathecalMerck & CoNeurologicalNew ZealandPharmaceuticalStrattera

Torrent to acquire Indian branded formulations from Elder

13-12-2013

Torrent Pharmaceuticals saw its shares rise 7% to 349 rupees after it said it is acquiring the branded…

Asia-PacificElder PharmaceuticalsIndiaMergers & AcquisitionsNeurologicalPharmaceuticalTorrent PharmaceuticalsWomen's Health

Review of key drivers of migraine market growth through 2022

06-12-2013

Use of Allergan’s Botox (botulinum toxin type A) for the prophylactic treatment of chronic migraine…

AllerganAsia-PacificBotoxCoLucid PharmaceuticalsEuropelasmiditanLevadexMarkets & MarketingNeurologicalNorth AmericaPharmaceutical

Takeda to commercialize Teva’s glatiramer acetate for MS in Japan

Takeda to commercialize Teva’s glatiramer acetate for MS in Japan

05-12-2013

Revealing an earlier agreement yesterday, Israel’s Teva Pharmaceutical Industries and Japan’s largest…

Asia-PacificCopaxoneGlatiramer AcetateLicensingNeurologicalPharmaceuticalRegulationTakeda PharmaceuticalsTeva Pharmaceutical Industries

New Zealand views access to sugammadex and atomoxetine and baclofen injection funding

02-12-2013

New Zealand’s Pharmaceutical Management Agency PHARMAC is seeking feedback on the following proposals…

Asia-PacificBridionEli LillyLioresal IntrathecalMerck & CoNeurologicalNew ZealandPharmaceuticalRegulationStrattera

Otsuka and Lundbeck’s schizophrenia drug Abilify Maintena approved in EU

Otsuka and Lundbeck’s schizophrenia drug Abilify Maintena approved in EU

21-11-2013

Japan’s Otsuka Pharmaceutical (TYO: 4768) and partner Lundbeck (LUN: CO) have received approval from…

Abilify MaintenaAsia-PacificEuropeLundbeckNeurologicalOtsukaPharmaceuticalRegulation

Incidence of post-herpetic neuralgia set for steady increase by 2022

11-11-2013

Due to the growth of the elderly population worldwide, the number of post-herpetic neuralgia (PHN) incident…

Asia-PacificEuropeMarkets & MarketingNeurologicalNorth AmericaPharmaceutical

Through 2022, growth in the neuropathic pain drug market will be constrained by generics

05-11-2013

The loss of US and European market exclusivity of three sales-leading neuropathic pain (NP) agents -…

Asia-PacificCymbaltaEli LillyEndo PharmaceuticalsEuropeLidodermLyricaMarkets & MarketingNeurologicalNorth AmericaPfizerPharmaceutical

Eisai seeks expanded Japanese indication for Aricept

Eisai seeks expanded Japanese indication for Aricept

01-11-2013

Japanese drug major Eisai says it has filed an application for its already marketed anti-Alzheimer's…

AriceptAsia-PacificEisaiNeurologicalPharmaceuticalRegulation

Nippon Shinyaku and Pfizer conclude exclusive sales promotion on Tramal

30-09-2013

Nippon Shinyaku and Pfizer have concluded an exclusive sales promotion consignment contract in Japan…

Asia-PacificLicensingMarkets & MarketingNeurologicalNippon ShinyakuPfizerPharmaceuticalTramadol Hydrochloride

New Zealand reaches agreement with Sanofi to fund ALS drug

11-09-2013

New Zealand's Pharmaceutical Management Agency PHARMAC has announce the approval of an agreement with…

Asia-PacificNeurologicalPharmaceuticalRare diseasesRegulationRilutekSanofi

Eisai gains WHO prequalification for DEC; launches high-dose Aricept in Korea

27-08-2013

Japanese drug major Eisai (TYO: 4523) has received prequalification from the World Health Organization…

AriceptAsia-PacificdiethylcarbamazineEisaiMarkets & MarketingNeurologicalPharmaceuticalRegulationTropical diseases

New Zealand approves proposals diazepam, gabapentin and naltrexone listing

12-07-2013

New Zealand's Pharmaceutical Management Agency PHARMAC has announced the approval of proposals relating…

Asia-PacificdiazepamgabapentinGenericsnaltrexoneNeurologicalPharmaceuticalRegulation

Proposal for a sole supply arrangement for fentanyl patches in New Zealand

08-07-2013

New Zealand's Pharmaceutical Management Agency, PHARMAC, is seeking feedback on a proposal to list a…

Asia-PacificfentanylFentanyl SandozNeurologicalNovartisPharmaceuticalPricingRegulationSandoz

Kyowa Hakko launches PD drug Nouriast and files for additional indication of fluorouracil in Japan

31-05-2013

Japanese drugmaker Kyowa Hakko Kirin (TYO: 4151) say that it launched its novel Parkinson's disease drug…

Asia-PacificfluorouracilKyowa Hakko KirinMarkets & MarketingNeurologicalNouriastOncologyPharmaceuticalRegulation

Asia-Pacific nuclear medicine/radiopharmaceuticals market to be worth $825 million by 2017

28-05-2013

The Asia-Pacific radiopharmaceutical market was valued at $500.8 million in 2012 and is poised to reach…

Asia-PacificMarkets & MarketingNeurologicalPharmaceutical

Japan's Eisai to set up parenteral facility in China

28-04-2013

Japanese drug major Eisai (TYO; 4523) says that it has decided to establish a new parenteral facility…

Asia-PacificEisaiMethycobalNeurologicalPharmaceuticalProduction

FDA approves Eisai's Aciphex Sprinkle for GERD in children; Inovelon OKed in Japan

28-03-2013

Japanese drug major Eisai (TYO: 4523) says that the US Food and Drug Administration has approved Aciphex…

AciphexAsia-PacificEisaiGastro-intestinalsInovelonNeurologicalNorth AmericaPharmaceuticalRegulation

Kyowa Hakko and Astellas get new indication for Pasetocin and Sawacillin; latter applies for new Dormicum use

21-02-2013

Japanese drug major Kyowa Hakko Kirin (TYO: 4151) and Astellas Pharma (TYO: 4503) have jointly announced…

Asia-PacificAstellas PharmaDormicumGastro-intestinalsKyowa Hakko KirinNeurologicalPasetocinPharmaceuticalRegulationSawacillin

1 to 25 of 52 results

Company Spotlight

ImmunoGen

ImmunoGen

Back to top